Is ICH E6(R3) Stalling?
Despite high awareness, ICH E6(R3) adoption is stalling, only 19% of organizations report significant change.
Despite high awareness, ICH E6(R3) adoption is stalling, only 19% of organizations report significant change.
Early alignment on risk tolerance is essential to ensure efficient, compliant trial execution.
TRI Fest 2025 brought our team together for a day of collaboration and a bit of friendly chaos.
This World Patient Safety Day, we’re shining a light on how healthcare professionals can build safety into every interaction.
This webinar unpacked the major shifts in ICH E6 (R3), showing how teams can embrace RBQM.
ICH E6 (R3) is here, but only 19% of the industry is ready. While awareness is high, meaningful action is lagging.
TRI is proud to join the Veeva R&D Summit as a Product Partner, showcasing our collaboration.
Explore five common mistakes that can derail your clinical trial and how OPRA helps teams manage risk.
Discover how TRI is transforming clinical research through smarter, data-driven solutions.